PURPOSE: The aim was to assess changes of @entity5 @entity519 during primary radiochemotherapy (RCT) for @entity135 ( @entity135 ) and to evaluate their relationship with treatment outcome. MATERIAL AND METHODS: @entity519 was assessed by @entity9241 -PET in weeks 0, 2 and 5 of RCT. The @entity5 volume (TV) was determined using FDG-PET/MRI/CT co-registered images. The level of @entity519 was quantified on @entity9241 -PET as TBRmax (SUVmaxTV/SUVmean background). The @entity519 subvolume (HSV) was defined as TV that showed @entity9241 uptake    1.4 times blood pool activity. RESULTS: Sixteen consecutive @entity1 (T3-4, N+, M0) were included (mean follow-up 31, median 44months). Mean TBRmax decreased significantly (p<0.05) from 1.94 to 1.57 (week 2) and 1.27 (week 5). Mean HSV in week 2 and week 5 ( @entity1704 =5.8ml, @entity1704 =0.3ml) were significantly (p<0.05) smaller than at baseline ( @entity3307 =15.8ml). Kaplan-Meier plots of local recurrence free survival stratified at the median TBRmax showed superior local control for @entity5 , the difference being significant at baseline and after 2weeks (p=0.031, p=0.016). CONCLUSIONS: @entity9241 -PET documented that in most @entity135 reoxygenation starts early during RCT and is correlated with better outcome.

Serial XXXX PET during radiochemotherapy for locally advanced @entity135 and its correlation with outcome.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer', 'HNC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['less hypoxic tumours', 'tumour'] @entity9241 :: ('MESH:C031843', 'Chemical') :: ['FMISO'] @entity519 :: ('MESH:D000860', 'Disease') :: ['Hypoxia', 'hypoxic', 'hypoxia'] @entity1704 :: ('10310', 'Species') :: ['HSV3', 'HSV2'] @entity3307 :: ('10298', 'Species') :: ['HSV1']
@entity9241 :: (MESH:C031843,Chemical) :: ['[18F]-fluoromisonidazole']
